| NCT03960437 |
The Effect of Etelcalcetide on CKD-MBD |
https://ClinicalTrials.gov/show/NCT03960437 |
Recruiting |
Columbia University |
2021-06-30 |
| NCT03822507 |
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia |
https://ClinicalTrials.gov/show/NCT03822507 |
Recruiting |
Kyowa Kirin Co., Ltd. |
2021-03-31 |
| NCT03299244 |
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT |
https://ClinicalTrials.gov/show/NCT03299244 |
Completed |
Amgen |
2020-04-08 |
| NCT03283098 |
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 |
https://ClinicalTrials.gov/show/NCT03283098 |
Completed |
Amgen |
2019-02-04 |
| NCT03226171 |
Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT03226171 |
Completed |
Sanwa Kagaku Kenkyusho Co., Ltd. |
2018-09-11 |
| NCT03182699 |
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients |
https://ClinicalTrials.gov/show/NCT03182699 |
Completed |
Medical University of Vienna |
2019-12-20 |
| NCT03123406 |
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT |
https://ClinicalTrials.gov/show/NCT03123406 |
Completed |
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. |
2019-04-20 |
| NCT02895061 |
Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients. |
https://ClinicalTrials.gov/show/NCT02895061 |
Completed |
Phramongkutklao College of Medicine and Hospital |
2015-10-31 |
| NCT02859896 |
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis |
https://ClinicalTrials.gov/show/NCT02859896 |
Recruiting |
Sanofi |
2022-04-05 |
| NCT02830789 |
Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass |
https://ClinicalTrials.gov/show/NCT02830789 |
Completed |
University of Aarhus |
2017-05-31 |
| NCT02341417 |
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis |
https://ClinicalTrials.gov/show/NCT02341417 |
Completed |
Amgen |
2017-03-15 |
| NCT02549417 |
Phase 3 Study of KHK7580 |
https://ClinicalTrials.gov/show/NCT02549417 |
Completed |
Kyowa Kirin Co., Ltd. |
2016-12-22 |
| NCT02549404 |
Phase 3 Study of KHK7580 |
https://ClinicalTrials.gov/show/NCT02549404 |
Completed |
Kyowa Kirin Co., Ltd. |
2016-12-06 |
| NCT02549391 |
Phase 3 Study of KHK7580 |
https://ClinicalTrials.gov/show/NCT02549391 |
Completed |
Kyowa Kirin Co., Ltd. |
2016-11-30 |
| NCT02524041 |
Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT02524041 |
Completed |
Centre Hospitalier Universitaire de Saint Etienne |
2016-04-30 |
| NCT02464072 |
Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis |
https://ClinicalTrials.gov/show/NCT02464072 |
Active, not recruiting |
University of Sao Paulo General Hospital |
2021-03-31 |
| NCT02282813 |
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 |
https://ClinicalTrials.gov/show/NCT02282813 |
Completed |
OPKO Health, Inc. |
2015-05-31 |
| NCT02274623 |
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid |
https://ClinicalTrials.gov/show/NCT02274623 |
Completed |
OPKO Health, Inc. |
2017-02-27 |
| NCT02216656 |
Phase 2 Study of KHK7580 |
https://ClinicalTrials.gov/show/NCT02216656 |
Completed |
Kyowa Kirin Co., Ltd. |
2015-02-28 |
| NCT02143271 |
Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis |
https://ClinicalTrials.gov/show/NCT02143271 |
Completed |
Kyowa Kirin Co., Ltd. |
2014-12-31 |
| NCT02133404 |
A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis |
https://ClinicalTrials.gov/show/NCT02133404 |
Completed |
Astellas Pharma Inc |
2014-11-10 |
| NCT02102204 |
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis |
https://ClinicalTrials.gov/show/NCT02102204 |
Completed |
Amgen |
2016-11-04 |
| NCT01290029 |
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT01290029 |
Completed |
Amgen |
2015-09-23 |
| NCT02056730 |
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid |
https://ClinicalTrials.gov/show/NCT02056730 |
Completed |
Chulalongkorn University |
2015-02-28 |
| NCT02054572 |
Pharmacokinetics and Excretion of [¹â´C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis |
https://ClinicalTrials.gov/show/NCT02054572 |
Completed |
Amgen |
2014-04-15 |
| NCT01939977 |
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. |
https://ClinicalTrials.gov/show/NCT01939977 |
Completed |
Fundación Senefro |
2015-09-30 |
| NCT01935856 |
Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis |
https://ClinicalTrials.gov/show/NCT01935856 |
Completed |
Kyowa Kirin Co., Ltd. |
2014-03-31 |
| NCT01932970 |
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide |
https://ClinicalTrials.gov/show/NCT01932970 |
Completed |
Amgen |
2014-01-14 |
| NCT01922843 |
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis |
https://ClinicalTrials.gov/show/NCT01922843 |
Completed |
Deltanoid Pharmaceuticals |
2014-05-31 |
| NCT01896232 |
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet |
https://ClinicalTrials.gov/show/NCT01896232 |
Completed |
Amgen |
2014-11-12 |
| NCT01788046 |
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis |
https://ClinicalTrials.gov/show/NCT01788046 |
Completed |
Amgen |
2014-04-14 |
| NCT01785875 |
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis |
https://ClinicalTrials.gov/show/NCT01785875 |
Completed |
Amgen |
2015-07-01 |
| NCT01785849 |
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis |
https://ClinicalTrials.gov/show/NCT01785849 |
Completed |
Amgen |
2014-05-22 |
| NCT01704079 |
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency |
https://ClinicalTrials.gov/show/NCT01704079 |
Completed |
OPKO Health, Inc. |
2014-08-31 |
| NCT01653379 |
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01653379 |
Completed |
Deltanoid Pharmaceuticals |
2014-07-31 |
| NCT01651000 |
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency |
https://ClinicalTrials.gov/show/NCT01651000 |
Completed |
OPKO Health, Inc. |
2014-07-31 |
| NCT01506947 |
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients |
https://ClinicalTrials.gov/show/NCT01506947 |
Completed |
AbbVie |
2016-04-07 |
| NCT01414114 |
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder |
https://ClinicalTrials.gov/show/NCT01414114 |
Completed |
KAI Pharmaceuticals |
2012-05-21 |
| NCT01382212 |
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis |
https://ClinicalTrials.gov/show/NCT01382212 |
Completed |
AbbVie |
2015-04-30 |
| NCT01341782 |
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01341782 |
Completed |
AbbVie |
2012-04-30 |
| NCT04064827 |
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
https://ClinicalTrials.gov/show/NCT04064827 |
Recruiting |
AbbVie |
2024-03-09 |
| NCT03969329 |
A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis |
https://ClinicalTrials.gov/show/NCT03969329 |
Recruiting |
Amgen |
2022-06-29 |
| NCT03801980 |
Phase 3 Study of SK-1403 |
https://ClinicalTrials.gov/show/NCT03801980 |
Completed |
Sanwa Kagaku Kenkyusho Co., Ltd. |
2019-12-17 |
| NCT03633708 |
Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis |
https://ClinicalTrials.gov/show/NCT03633708 |
Recruiting |
Amgen |
2023-01-31 |
| NCT03626948 |
SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis |
https://ClinicalTrials.gov/show/NCT03626948 |
Completed |
Sanwa Kagaku Kenkyusho Co., Ltd. |
2020-02-04 |
| NCT03602261 |
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI |
https://ClinicalTrials.gov/show/NCT03602261 |
Recruiting |
OPKO Health, Inc. |
2020-12-31 |
| NCT03588884 |
Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI |
https://ClinicalTrials.gov/show/NCT03588884 |
Recruiting |
OPKO Health, Inc. |
2020-03-17 |
| NCT01254565 |
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01254565 |
Completed |
KAI Pharmaceuticals |
2011-07-31 |
| NCT01220050 |
Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01220050 |
Completed |
Mario Negri Institute for Pharmacological Research |
2012-07-31 |
| NCT01219855 |
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) |
https://ClinicalTrials.gov/show/NCT01219855 |
Completed |
OPKO Health, Inc. |
2011-11-30 |
| NCT01191762 |
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT01191762 |
Completed |
Phelps, Kenneth R., M.D. |
2012-08-31 |
| NCT01181531 |
Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis |
https://ClinicalTrials.gov/show/NCT01181531 |
Completed |
Amgen |
2012-07-17 |
| NCT01178450 |
Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation |
https://ClinicalTrials.gov/show/NCT01178450 |
Completed |
Hospital Universitari de Bellvitge |
2014-09-30 |
| NCT01167309 |
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients |
https://ClinicalTrials.gov/show/NCT01167309 |
Completed |
LEO Pharma |
2011-10-31 |
| NCT01143987 |
Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01143987 |
Completed |
Chinese University of Hong Kong |
2013-02-28 |
| NCT01138475 |
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery |
https://ClinicalTrials.gov/show/NCT01138475 |
Completed |
William Beaumont Hospitals |
2015-08-31 |
| NCT01134562 |
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01134562 |
Completed |
KAI Pharmaceuticals |
2011-04-02 |
| NCT01134549 |
Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT01134549 |
Completed |
KAI Pharmaceuticals |
2010-07-31 |
| NCT01115543 |
Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT01115543 |
Completed |
Mahidol University |
2009-08-31 |
| NCT01101113 |
Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level |
https://ClinicalTrials.gov/show/NCT01101113 |
Completed |
Seoul National University Hospital |
2012-03-31 |
| NCT01100723 |
Trial to Optimize Mineral Outcomes in Dialysis Patients |
https://ClinicalTrials.gov/show/NCT01100723 |
Completed |
University of Colorado, Denver |
2011-08-31 |
| NCT01025128 |
Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density |
https://ClinicalTrials.gov/show/NCT01025128 |
Completed |
Clalit Health Services |
2014-07-31 |
| NCT00999037 |
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00999037 |
Completed |
University of California, Los Angeles |
2015-06-30 |
| NCT00990704 |
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00990704 |
Completed |
Abbott |
2010-05-31 |
| NCT00977080 |
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D |
https://ClinicalTrials.gov/show/NCT00977080 |
Completed |
Abbott |
2011-05-31 |
| NCT00958451 |
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
https://ClinicalTrials.gov/show/NCT00958451 |
Completed |
Salem Veterans Affairs Medical Center |
2011-01-31 |
| NCT00891813 |
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose |
https://ClinicalTrials.gov/show/NCT00891813 |
Completed |
Abbott |
2010-09-30 |
| NCT00888069 |
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects |
https://ClinicalTrials.gov/show/NCT00888069 |
Completed |
OPKO Health, Inc. |
2009-11-30 |
| NCT03660800 |
Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects |
https://ClinicalTrials.gov/show/NCT03660800 |
Completed |
OPKO Health, Inc. |
2018-10-24 |
| NCT02833857 |
A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis |
https://ClinicalTrials.gov/show/NCT02833857 |
Completed |
Amgen |
2018-10-31 |
| NCT00828347 |
Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) |
https://ClinicalTrials.gov/show/NCT00828347 |
Completed |
Kumamoto University |
2009-07-31 |
| NCT00823303 |
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) |
https://ClinicalTrials.gov/show/NCT00823303 |
Completed |
Washington University School of Medicine |
2013-05-31 |
| NCT00803712 |
20070360 Incident Dialysis |
https://ClinicalTrials.gov/show/NCT00803712 |
Completed |
Amgen |
2010-12-09 |
| NCT00792857 |
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) |
https://ClinicalTrials.gov/show/NCT00792857 |
Completed |
OPKO Health, Inc. |
2009-09-30 |
| NCT00781417 |
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00781417 |
Completed |
Atlanta VA Medical Center |
2011-10-31 |
| NCT00754442 |
Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00754442 |
Completed |
University of Maryland, Baltimore |
2008-08-31 |
| NCT00742716 |
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00742716 |
Completed |
OPKO Health, Inc. |
2010-02-28 |
| NCT00701805 |
Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) |
https://ClinicalTrials.gov/show/NCT00701805 |
Completed |
Abbott |
2009-12-31 |
| NCT00667576 |
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis |
https://ClinicalTrials.gov/show/NCT00667576 |
Completed |
Abbott |
2009-03-31 |
| NCT00800358 |
Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00800358 |
Completed |
Penang Hospital, Malaysia |
2009-10-31 |
| NCT00601328 |
Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions |
https://ClinicalTrials.gov/show/NCT00601328 |
Completed |
West-Ward Pharmaceutical |
2003-08-31 |
| NCT00587158 |
Oral Paricalcitol in Kidney Transplant Recipients |
https://ClinicalTrials.gov/show/NCT00587158 |
Completed |
Mayo Clinic |
2011-11-30 |
| NCT00560300 |
Regulation of Bone Formation in Renal Osteodystrophy |
https://ClinicalTrials.gov/show/NCT00560300 |
Completed |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
NA |
| NCT00537979 |
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis |
https://ClinicalTrials.gov/show/NCT00537979 |
Completed |
Abbott |
2010-07-31 |
| NCT00528788 |
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis |
https://ClinicalTrials.gov/show/NCT00528788 |
Completed |
Duke University |
2012-08-31 |
| NCT00463021 |
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection |
https://ClinicalTrials.gov/show/NCT00463021 |
Completed |
Sanofi |
NA |
| NCT00454350 |
A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis |
https://ClinicalTrials.gov/show/NCT00454350 |
Completed |
Sanofi |
NA |
| NCT00431496 |
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) |
https://ClinicalTrials.gov/show/NCT00431496 |
Completed |
Amgen |
2009-06-30 |
| NCT00418600 |
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis |
https://ClinicalTrials.gov/show/NCT00418600 |
Completed |
Sanofi |
2007-06-30 |
| NCT00397475 |
Evaluation of Colecalciferol Substitution in Dialysis Patients |
https://ClinicalTrials.gov/show/NCT00397475 |
Completed |
University Hospital, Saarland |
NA |
| NCT00379899 |
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis |
https://ClinicalTrials.gov/show/NCT00379899 |
Completed |
Amgen |
2009-05-31 |
| NCT00352170 |
Calcium and Vitamin D Malnutrition in Elderly Women |
https://ClinicalTrials.gov/show/NCT00352170 |
Completed |
Creighton University |
2005-07-31 |
| NCT00345839 |
E.V.O.L.V.E. Trialâ„¢: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events |
https://ClinicalTrials.gov/show/NCT00345839 |
Completed |
Amgen |
2012-04-10 |
| NCT00307840 |
Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00307840 |
Completed |
Papageorgiou General Hospital |
NA |
| NCT00288873 |
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity |
https://ClinicalTrials.gov/show/NCT00288873 |
Completed |
Weill Medical College of Cornell University |
2007-07-31 |
| NCT00285467 |
Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00285467 |
Completed |
Indiana University |
2009-12-31 |
| NCT00261950 |
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease |
https://ClinicalTrials.gov/show/NCT00261950 |
Completed |
Amgen |
2011-05-31 |
| NCT00257920 |
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease |
https://ClinicalTrials.gov/show/NCT00257920 |
Completed |
Abbott |
2008-01-31 |
| NCT00211939 |
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients |
https://ClinicalTrials.gov/show/NCT00211939 |
Completed |
Nabi Biopharmaceuticals |
2006-12-31 |
| NCT00135304 |
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00135304 |
Completed |
Amgen |
2006-10-31 |
| NCT00132431 |
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00132431 |
Completed |
Amgen |
NA |
| NCT00123461 |
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00123461 |
Completed |
Sanofi |
2007-10-31 |
| NCT00117052 |
SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism |
https://ClinicalTrials.gov/show/NCT00117052 |
Completed |
Amgen |
2005-11-30 |
| NCT00110929 |
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD) |
https://ClinicalTrials.gov/show/NCT00110929 |
Completed |
Amgen |
NA |
| NCT00094484 |
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis |
https://ClinicalTrials.gov/show/NCT00094484 |
Completed |
Amgen |
NA |
| NCT00073710 |
Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium |
https://ClinicalTrials.gov/show/NCT00073710 |
Completed |
Abbott |
NA |
| NCT00053547 |
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis |
https://ClinicalTrials.gov/show/NCT00053547 |
Completed |
Abbott |
NA |
| NCT00042653 |
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis |
https://ClinicalTrials.gov/show/NCT00042653 |
Completed |
Amgen |
2003-07-31 |
| NCT00042432 |
Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients |
https://ClinicalTrials.gov/show/NCT00042432 |
Completed |
Amgen |
2003-03-31 |
| NCT00037635 |
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients |
https://ClinicalTrials.gov/show/NCT00037635 |
Completed |
Amgen |
2003-03-31 |